← All trials
NCT06263816
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2024
- Primary completion
- Oct 15, 2029
- Completion date
- Jun 15, 2030
- First posted
- Feb 16, 2024
- Last posted
- Feb 20, 2024
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University Hospital, ToursLead sponsor
- University of BurgundyCollaborator
- University of LyonCollaborator
- University of ToulouseCollaborator
- University of ReimsCollaborator
- University of AngersCollaborator
- University of Caen-NormandieCollaborator
- University of StrasbourgCollaborator
- University of NantesCollaborator
- University Hospital, ToursOfficial
- University of MontpellierCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.